Horizon Pharma is buying Hyperion Therapeutics for about $1.1 billion, gaining two treatments for genetic disorders.
6 hours ago
Intensive care units across the United States vary widely in how they manage the care of patients who have set preexisting limits on life-sustaining therapies, such as authorizing do-not-resuscitate (DNR) orders and prohibiting ...
3 hours ago
- Pages: 1